Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive

Patients with BRAF V600 (BRAF) mutated metastatic melanoma are eligible for therapy with both immune checkpoint inhibitors and targeted therapies, making treatment choice a complex decision. The present study aimed to describe patterns of treatment with immunotherapy and targeted therapy and BRAF te...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghate, Sameer, Ionescu-Ittu, Raluca, Burne, Rebecca, Ndife, Briana, Laliberté, François, Nakasato, Antonio, Duh, Mei Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
ORIGINAL ARTICLES: Epidemiology of melanoma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494034/
https://www.ncbi.nlm.nih.gov/pubmed/30247203
http://dx.doi.org/10.1097/CMR.0000000000000504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494034/
https://www.ncbi.nlm.nih.gov/pubmed/30247203
http://dx.doi.org/10.1097/CMR.0000000000000504

Ejemplares similares